Abstract
Objective. To examine the joint association of moderate-to-vigorous intensity physical activity (MVPA) and sedentary behavior with the risk of developing functional limitation 4 years later in adults with knee osteoarthritis (OA). Methods. Using 48-month (baseline) accelerometry data from the Osteoarthritis Initiative, we classified participants as Active-Low Sedentary (≥ 1 10-min bout/week of MVPA, lowest tertile for standardized sedentary time), Active-High Sedentary (≥ 1 10-min bout/week of MVPA, top 2 tertiles for standardized sedentary time), Inactive-Low Sedentary (zero 10-min bouts/week of MVPA, lowest tertile for standardized sedentary time), and Inactive-High Sedentary (zero 10-minute bouts/week of MVPA, top 2 tertiles for standardized sedentary time) groups. Functional limitation was defined as > 12 seconds for the 5-repetition sit-to-stand test (5XSST) and < 1.22 m/s gait speed during the 20-meter walk test. To investigate the association of exposure groups with risk of developing functional limitation 4 years later, we calculated adjusted risk ratios (aRR; adjusted for potential confounders). Results. Of 1091 and 1133 participants without baseline functional limitation, based on the 5XSST and 20-meter walk test, respectively, 15% and 21% developed functional limitation 4 years later. The Inactive-Low Sedentary and Inactive-High Sedentary groups had increased risk of developing functional limitations compared to the Active-Low Sedentary and Active-High Sedentary groups. The Inactive-Low Sedentary group had 72% (aRR 1.72, 95% CI 1.00-2.94) and 52% (aRR 1.52, 95% CI 1.03-2.25) more risk of developing functional limitation based on the 5XSST and 20-meter walk test, respectively, compared to the Active-Low Sedentary group. Conclusion. Regardless of sedentary category, being inactive (zero 10-min bouts/week in MVPA) may increase the risk of developing functional limitation in adults with knee OA.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1458-1464 |
| Number of pages | 7 |
| Journal | Journal of Rheumatology |
| Volume | 48 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2021 |
Funding
This work was supported by the University Doctoral fellowship award from Unidel Foundation to HM, and the National Institute of Health (NIH; grant numbers R21-AR071079-01A1, K12HD055931-01, K23AR070913, and U54 GM104941 to DKW; F32AR073090 to LMT; and T32-HD007490 to DV). This manuscript was prepared using an Osteoarthritis Initiative (OAI) public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The OAI is a public-private partnership composed of 5 contracts (N01-AR-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, and N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the NIH. This work was supported by the University Doctoral fellowship award from Unidel Foundation to HM, and the National Institute of Health (NIH; grant numbers R21-AR071079-01A1, K12HD055931-01, K23AR070913, and U54 GM104941 to DKW; F32AR073090 to LMT; and T32-HD007490 to DV). This manuscript was prepared using an Osteoarthritis Initiative (OAI) public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The OAI is a public-private partnership composed of 5 contracts (N01-AR-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, and N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the NIH. 1H. Master, PT, PhD, MPH, Department of Physical Therapy, College of Health Sciences, and Biomechanics and Movement Science Interdisciplinary Program, University of Delaware, Newark, Delaware, and Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee; 2L.M. Thoma, PT, DPT, PhD, Division of Physical Therapy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 3D.D. Dunlop, PhD, Department of Medicine, and Department of Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois; 4M.B. Christiansen, PT, DPT, PhD, Fern Health, Inc. New York, New York; 5D. Voinier, PT, DPT, D.K. White, PT, ScD, Department of Physical Therapy, College of Health Sciences, and Biomechanics and Movement Science Interdisciplinary Program, University of Delaware, Newark, Delaware, USA. There are no conflicts of interest and the authors have no disclosures. Address correspondence to D.K. White, STAR Health Sciences Complex, 540 S. College Avenue Newark, DE 19713, USA. Email: [email protected]. Accepted for publication January 20, 2021.
Keywords
- Functional limitation
- Moderate-to-vigorous intensity physical activity
- Osteoarthritis
- Physical activity
- Sedentary behavior
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology